An interventional study of Non-intubated VATS for mediastinal neoplasm and Intubated VATS for mediastinal neoplasm in Mediastinal Neoplasm, VATS and Tubeless, sponsored by Shuben Li. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by Shuben Li · Not applicable, Interventional, and Treatment
In recent year, non-intubated anesthesia had emerged as an available and promising alternative for thoracic procedure. However, its safety and feasibility in video-assisted thoracoscopic surgery (VATS) for mediastinal neoplasm remain controversial. This randomized controlled trial is designed to evaluate the impact of the non-intubated approach on surgical and perioperative outcomes in patients undergoing mediastinal neoplasm resection.
Non-intubated anesthesia has gained widespread adoption in recent years, representing a significant advancement in both thoracic surgery and anesthetic practice. The surgical safety and feasibility of tubeless VATS for mediastinal neoplasm has been confirmed. However, the oncological long-term outcomes of RATS lobectomy has not been studied by randomized controlled trial. Accordingly, this randomized controlled trial aims to evaluate whether the non-intubated approach provides comparable short-term and long-term outcomes to the conventional intubated technique in VATS for mediastinal neoplasm resection.
Exclusion Criteria:
Patients received tubeless VATS for mediastinal neoplasm
Procedure: Non-intubated VATS for mediastinal neoplasm
Patients received VATS mediastinal neoplasm resection under intubated general anesthesia.
Procedure: Intubated VATS for mediastinal neoplasm
Non-intubated VATS for mediastinal neoplasm
Intubated VATS for mediastinal neoplasm
Conversion rate to open surgery
Proportion of patients requiring conversion from VATS to open surgery.
Time frame: postoperative in-hospital stay up to 30 days
Conversion rate to intubated anesthesia
Proportion of patients requiring conversion from non-intubated approach to intubated anesthesia
Time frame: postoperative in-hospital stay up to 30 days
Postoperative complication rate
Incidence and severity of treatment-related adverse events, classified by Clavien-Dindo for surgical complications and CTCAE v5.0 for systemic adverse events.
Time frame: postoperative in-hospital stay up to 30 days
R0 rate
R0 resection rate
Time frame: postoperative in-hospital stay up to 30 days
Operation time
Operative time was defined as the time between the start of the surgery (incision) and the finish of surgery (closure of the skin).
Time frame: postoperative in-hospital stay up to 30 days
Intraoperative bleeding loss
The volume of bleeding during the surgery.
Time frame: postoperative in-hospital stay up to 30 days
ICU stay
ICU stay (in days), defined as the duration from ICU admission post-surgery to ICU discharge.
Time frame: postoperative in-hospital stay up to 30 days
Hospital stay
Hospital stay, defined as the duration from the day of surgery to the day of discharge.
Time frame: postoperative in-hospital stay up to 30 days
Volume of postoperative drainage
Volume of postoperative drainage, measured from the end of surgery until drain removal.
Time frame: postoperative in-hospital stay up to 30 days
1-year disease-free survival (DFS)
1-year disease-free survival (DFS), defined as the percentage of patients alive without evidence of tumor recurrence or progression at 12 months.
Time frame: 1 year after surgery
1-year overall survival(OS)
1-year overall survival(OS), defined as the percentage of patients alive at 12 months from the date of surgery or treatment initiation, irrespective of disease recurrence or progression.
Time frame: 1 year after surgery
Quality of life (QOL) at 3 month
3 months after discharge
Time frame: Quality of life (QOL) at 3 months post-discharge, as measured by [specify QOL scale], reflecting patient-reported physical, emotional, and social well-being.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shuben Li